ArticleAdvanced healthcare materials2020
Lipid-Modified Aminoglycosides for mRNA Delivery to the Liver.
Article in Advanced healthcare materials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- A novel machine learning framework-based rapid screening of ionizable lipids in LNPs for highly-efficient mRNA expression.Acta pharmaceutica Sinica. B · 2026Article
- Developing the Strategy to Use Silk Spheres for Efficient, Targeted Delivery of Oligonucleotide Therapeutics to Cancer Cells.International journal of nanomedicine · 2025Article
- Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Current landscape of mRNA technologies and delivery systems for new modality therapeutics.Journal of biomedical science · 2024Review
- From structural design to delivery: mRNA therapeutics for cancer immunotherapy.Exploration (Beijing, China) · 2024Review
- Composition of lipid nanoparticles for targeted delivery: application to mRNA therapeutics.Frontiers in pharmacology · 2024Review
- Delivery of nucleic acids using nanomaterials.Molecular biomedicine · 2023Review
- 'Passive' nanoparticles for organ-selective systemic delivery: design, mechanism and perspective.Chemical Society reviews · 2023Review
- mRNA nanodelivery systems: targeting strategies and administration routes.Biomaterials research · 2023Review
- Targeting materials and strategies for RNA delivery.Theranostics · 2023Review
- Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs.Nature reviews. Materials · 2023Review
- Advances in nanoparticle-based mRNA delivery for liver cancer and liver-associated infectious diseases.Nanoscale horizons · 2022Review
- Recent Advances in Lipid Nanoparticles for Delivery of mRNA.Pharmaceutics · 2022Review
- Zwitterionic Phospholipidation of Cationic Polymers Facilitates Systemic mRNA Delivery to Spleen and Lymph Nodes.Journal of the American Chemical Society · 2021Article
- New Applications of Lipid and Polymer-Based Nanoparticles for Nucleic Acids Delivery.Pharmaceutics · 2021Review
- Hydrophobic Optimization of Functional Poly(TPAE-co-suberoyl chloride) for Extrahepatic mRNA Delivery following Intravenous Administration.Pharmaceutics · 2021Article
- Lipids and Lipid Derivatives for RNA Delivery.Chemical reviews · 2021Review
- From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases.Acta biomaterialia · 2021Review
- Computational and Experimental Approaches to Investigate Lipid Nanoparticles as Drug and Gene Delivery Systems.Current topics in medicinal chemistry · 2021Review
- Lipid nanoparticles for mRNA delivery.Nature reviews. Materials · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Cationic lipid nanoparticles (LNPs) are widely used as carriers for delivery of nucleic acids. Most synthetic routes toward cationic lipids have derived from simple amine cores. Greater chemical diversity can be obtained through starting with natural products containing basic nitrogen atoms, which offers routes to more complex molecules. Natural building blocks are not extensively explored, such as aminoglycosides, which are both structurally and functionally interesting for developing new carriers for nucleic acid delivery. Herein, cationic lipid-modified aminoglycosides (CLAs) are explored as a family of vehicles for messenger RNA (mRNA) delivery. CLAs are synthesized from natural existing aminoglycosides coupling with alkyl epoxides and acrylates. The top hit (GT-EP10) is able to deliver Luc mRNA to C57BL/6 mice at a dose of 0.05 mg kg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.